Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 445 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: unfractionated heparin Clear all
Completed Phase 3 Interventional

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery

NCT00718224
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Semuloparin sodium, Enoxaparin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Cancer Venous Thromboembolism (VTE)

NCT02073682
View directory record Official record
Conditions
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cancer
Interventions
Edoxaban, Dalteparin, Low molecular weight heparin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Brandon, Florida • Jonesboro, Georgia • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

NCT00790335
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism, Post Thrombotic Syndrome
Interventions
Recombinant tissue plasminogen activator (rt-PA)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
16 Years to 75 Years
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
56
States / cities
Glendale, Arizona • Orange, California • Stanford, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 7, 2026, 10:47 AM EDT
Completed No phase listed Observational Results available

Observational Study of Citrate Based Dialysis in Pediatric Patients Receiving Hemodialysis

NCT01590550
View directory record Official record
Conditions
Complication of Dialysis
Interventions
Use of citrate based dialysate
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
1 Day to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 7, 2026, 10:47 AM EDT
Terminated Phase 2 Interventional Results available

Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial

NCT03003390
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
Yale University
Other
Eligibility
Up to 17 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 7, 2026, 10:47 AM EDT
Terminated Phase 4 Interventional Results available

Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin

NCT03296033
View directory record Official record
Conditions
Anticoagulants and Bleeding Disorders, Surgery, Regional Anesthesia Morbidity
Interventions
Enoxaparin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 100 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Results available

Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)

NCT01014403
View directory record Official record
Conditions
Venous Thromboembolism, Traumatic Brain Injury
Interventions
enoxaparin, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Dallas, Texas • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

NCT00433966
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Bivalirudin, Unfractionated heparin, Bare metal stent, Paclitaxel-eluting stent
Drug · Device
Lead sponsor
Cardiovascular Research Foundation, New York
Other
Eligibility
18 Years and older
Enrollment
3,602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 7, 2026, 10:47 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

NCT00790842
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
Lenalidomide, Dexamethasone, Anticoagulants
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
16
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 7, 2026, 10:47 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Reversing Glucose and Lipid-mediated Vascular Dysfunction

NCT04832009
View directory record Official record
Conditions
Blood Pressure, Hypertension
Interventions
Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 7, 2026, 10:47 AM EDT
Not listed Phase 3 Interventional

Pilot Feasibility and Safety of Administering Weight Adjusted Fixed LMWH Dose

NCT02486666
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Enoxaparin
Drug
Lead sponsor
Hamilton Health Sciences Corporation
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 2 Interventional

Carotid With Bivalirudin Angioplasty

NCT00812383
View directory record Official record
Conditions
Carotid Artery Disease
Interventions
RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement

NCT00641732
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
TAK-442, Enoxaparin
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,045 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 7, 2026, 10:47 AM EDT
Not listed Phase 3 Interventional

Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT)

NCT03147638
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia
Interventions
Warfarin, NOAC
Drug
Lead sponsor
Marshall University
Other
Eligibility
18 Years to 97 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 7, 2026, 10:47 AM EDT
Completed No phase listed Observational

User Performance Evaluation of the INRatio® Prothrombin Time (PT) Monitoring System With a New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity

NCT01036646
View directory record Official record
Conditions
Oral Anticoagulation
Interventions
Not listed
Lead sponsor
Abbott RDx Cardiometabolic
Other
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Loma Linda, California • Sacramento, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

NCT00457002
View directory record Official record
Conditions
Venous Thrombosis, Pulmonary Embolism
Interventions
Apixaban, Enoxaparin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years and older
Enrollment
6,758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
48
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 7, 2026, 10:47 AM EDT
Terminated Phase 2 Interventional

FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer

NCT00323011
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis

NCT01999179
View directory record Official record
Conditions
Venous Thrombosis, Neoplasms
Interventions
Heparin, Low-Molecular-Weight, or direct oral anticoagulants
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
Minneapolis, Minnesota • Columbus, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

NCT02981472
View directory record Official record
Conditions
Thrombosis
Interventions
Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
28 Days to 17 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
14
States / cities
Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 7, 2026, 10:47 AM EDT
Withdrawn Phase 2 Interventional

Safety of Heparin in Patients With Septic Shock

NCT01234285
View directory record Official record
Conditions
Sepsis
Interventions
heparin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

NCT02234843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 7, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

NCT02651428
View directory record Official record
Conditions
Kidney Failure, Chronic, Catheter-Related Infections
Interventions
Neutrolin, Heparin
Drug
Lead sponsor
CorMedix Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Riverside, California • San Dimas, California • Miami Gardens, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 7, 2026, 10:47 AM EDT
Terminated Phase 2 Interventional

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

NCT01518465
View directory record Official record
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
dalteparin, lenalidomide, dexamethasone, laboratory biomarker analysis
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 7, 2026, 10:47 AM EDT